Ignite Creation Date:
2025-12-24 @ 3:25 PM
Ignite Modification Date:
2025-12-29 @ 12:52 PM
Study NCT ID:
NCT04335292
Status:
RECRUITING
Last Update Posted:
2024-10-22
First Post:
2020-03-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
Sponsor:
Mark Vincent
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-01-06
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-01
Completion Date Type:
ESTIMATED
First Submit Date:
2020-03-06
First Submit QC Date:
None
Study First Post Date:
2020-04-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-18
Last Update Post Date:
2024-10-22
Last Update Post Date Type:
ACTUAL